Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro  by Gupta, Manisha et al.
07) 45–54
www.elsevier.com/locate/yviroVirology 364 (20Ebola virus infection of human PBMCs causes massive death of
macrophages, CD4 and CD8 T cell sub-populations in vitro☆
Manisha Gupta ⁎, Christina Spiropoulou, Pierre E. Rollin
Special Pathogens Branch, DVRD, Centers for Disease Control and Prevention, Mailstop G14, 1600 Clifton Road, Atlanta, GA 30333, USA
Received 9 November 2006; returned to author for revision 14 December 2006; accepted 6 February 2007
Available online 27 March 2007Abstract
Ebola virus causes an often fatal disease characterized by poor immune response and high inflammatory reaction in the patients. One of the
causes for poor immunity is virus-mediated apoptosis of lymphocytes in the host. In this study, we infected human PBMCs with Ebola Zaire virus
and study apoptosis of different cell types using flow cytometry. We have shown that Ebola virus causes bystander death of CD4 and CD8 T cells.
Cells infected with virus had 30–40% active caspase 3+, annexin-V+ and Bcl2low phenotype by day 8 PI as compared to inactivated virus-treated
cells. 60–70% of the macrophages were also dead by day 8 PI and had similar phenotype. Our data also showed that virus may induce death
signals in Fas+/FasL+ T lymphocytes and macrophages but did not upregulate Fas/FasL expression in these cells. Lastly, CD4, CD8 and CD14
cells were purified after infection and were studied for death signals by RNAse protection assay. We found an upregulation of TRAIL mRNA in
CD4 and CD8 T cells on day 7 PI. A two-fold increase in CD4 T cells and three-fold increase in CD8 T cells were observed in TRAIL mRNA
levels as compared to uninfected controls and inactive virus-treated cells. Surprisingly, we did not find any difference in TRAIL mRNA levels
between infected macrophages and uninfected controls. These data suggest that Ebola virus evades the immune response by causing massive
lymphocyte death. In addition, they may give an explanation on why the host is unable to produce a good antibody response in the absence of CD4
T cells.
© 2007 Elsevier Inc. All rights reserved.Keywords: Ebola virus; Apoptosis; Fas; FasL; TRAILIntroduction
Ebola virus infection causes severe and often fatal disease in
humans and non-human primates. Disease is characterized by
high levels of inflammatory cytokines that result in septic shock
and multiorgan failure (Bray and Mahanty, 2003). Ebola virus
replicates in a variety of cell types including macrophages,
epithelial cells, endothelial cells and hepatocytes and rapidly
spreads in the vital organs of the host. Poor immune response
and lymphopenia are among the hallmark features of the disease
(Baize et al., 1999; Sanchez et al., 2004). In vitro infection ofAbbreviations: FSC, forward scatter; GFP, green fluorescent protein; MOI,
multiplicity of infection; PBMCs, peripheral blood mononuclear cells; PI,
post-infection; TRAIL, tumor necrosis factor related apoptosis inducing ligand.
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function could be impaired (Mahanty et al., 2003). Previous
reports on samples collected from Ebola patients have shown a
decrease in the total number of peripheral blood mononuclear
cells (PBMCs) (Mahanty and Bray, 2004; Sanchez et al., 2004).
In Ebola patients' PBMCs, Baize et al. demonstrated a decrease
in mRNA levels of CD8, CD3 and IFN-γ, IL-4 and IL-2,
suggesting a lack of anti-viral immune response during in-
fection (Baize et al., 1999). Fatal patients do not develop anti-
Ebola antibodies before death and the appearance of anti-Ebola
IgG is also delayed in survivors (Busico et al., 1999). These
reports indirectly suggest that Ebola virus might cause apoptosis
of various cell populations.
In this study, we use an in vitro system in which human
PBMCs were infected with Ebola virus. Various cell types such
as CD4 T cells, CD8 T cells, B-cells, NK cells and macrophages
were studied for activation and apoptosis signals on various
days after infection. Our data indicate that 20–30% of CD4 and
46 M. Gupta et al. / Virology 364 (2007) 45–54CD8 T cells died during the course of infection and 70–80%
macrophages underwent apoptosis by day 8 post-infection (PI).
Ebola virus induced apoptotic signals in Fas+/FasL+ CD4 and
CD8 T cells. We also found an upregulation of TRAIL mRNA
in CD4 and CD8 T cells after Ebola virus infection, suggesting
that TRAIL may be playing a role in the induction of apoptosis
in T cells.
Results
Ebola virus causes massive CD4 T cell death
PBMCs from healthy volunteers were isolated and inoculated
with 0.5 MOI of either Ebola virus or gamma-irradiated
inactivated virus and studied for apoptosis using flow cytometric
methods. PBMCs were first studied for CD3 levels, CD4 levels,
forward and side scatter. We found a 21% decline in CD3 levels
on day 4 and a 44% decline on day 8 post-infection as compared
to uninfected controls and inactivated virus-treated cells (Table
1). Similarly a 30% decline in CD4 levels on day 4 and a 61%
decline on day 8 post-infection as compared to the controls
(Table 1). We also found an increase in the number of FSClow
CD3+4+ cells (mean channel value <200) after virus infection
(27% in infected cultures versus 17–18% in controls on day 4;
41% in infected cultures versus 21% on controls on day 8 post-
infection).
To further confirm that the FSClow cells were undergoing
apoptosis, we studied CD3+4+ T cells for Bcl2, active caspase 3
and annexin-V markers. On day 4 PI, 13–17% cells were Bcl2low
(Fig. 1) and remained the same on day 8 PI in both controls. In
virus-infected cells, there was a dramatic increase in Bcl2low cells.
The Bcl2low population increased from 31% on day 4 PI to 44%
on day 8 PI (Fig. 1). These Bcl2low cells were also FSClow. About
twice as many cells were dying by day 4 and three times more
cells were dying by day 8 PI compared to controls. SimilarTable 1
Data in table shows mean fluorescent intensity of different markers on
uninfected, inactivated virus-treated and live virus-infected PBMCs on days 4
and 8 post-infection
Isotype control Uninfected control Inactivated virus Live virus
Day 4
CD3 30±4 434±34 431±35 342±40
CD4 30±10 596±40 631±30 419±20
CD8 40±5 1965±120 2165±120 1203±120
CD14 30±7 1443±40 1195±35 220±20
Day 8
CD3 30±5 503±30 525±40 277±77
CD4 30±6 1079±40 1202±50 419±29
CD8 40±8 2590±120 2788±200 1051±45
CD14 30±4 2806±130 3315±150 169±55
Data are represented as mean±SD from five different experiments. Approxi-
mately 50,000 cells were counted in each sample. The numbers of CD3+CD4+ in
uninfected and inactivated virus-treated cells were 20,540±2200 and 21,613±
2400 respectively and 18,540±500 in infected cultures. Similarly CD3+8+ cells
were 12,500±590 and 12,200±400 in uninfected control and inactivated virus-
treated PBMCs and 12,800±540 in virus-infected cultures. Similar numbers
were found on day 8 post-infection.numbers were found with active caspase 3 markers. Quadrant
statistics was done for FSC and active caspase 3 on CD3+4+ T
cells. We found that in infected population 6–15% cells were
FSChigh and active caspase 3high as compared to 14–19% in the
uninfected control and the inactivated virus-treated cell popula-
tions on days 4 and 8 PI (Fig. 1). In the virus-infected group, 33%
of the cells were FSClow and active caspase 3high as compared to
16% in controls on day 4 PI (middle panel, Fig. 1). Also in this
group, the percentage of caspase 3high FSClow cell population
increased from 33% on day 4 PI to 52% on day 8 PI as compared
to 12–18% in control groups (lower right square, Fig. 1).We next
studied annexin-V as another apoptotic marker. We found
annexin-V markers on both FSChigh and FSClow cells. On day
4 PI, in two control groups, 18% cells were FSChigh and
annexin-V+ as compared to 2% in live virus-infected cells (top
right square, Fig. 1) whereas most of the annexin-V+ cells (21%)
were FSClow cells in infected cell population (lower right square,
Fig. 1). Similarly on day 8 PI, 42% of the cells were FSClow
annexin-V+ in infected cell population as compared to 1% in the
controls. In the control groups, all annexin-V+ cells were FSChigh
cells. These data together suggested that 15–30% CD3+4+ Tcells
were dying during the course of Ebola virus infection. They also
showed that active caspase 3 and annexin-V markers are
expressed in both blast cells (FSChigh) and small sized (FSClow)
cells. However increase in the frequency of active caspase 3high
and annexin-V+ cells was observed on FSClow cell population
and decrease in frequency of active caspase 3high and annexin-V+
in FSChigh cells infected with Ebola virus compared to uninfected
controls.
Ebola virus causes massive death of CD8 T cells
Infected PBMCs from healthy patients were inoculated with
0.5 MOI of Ebola Zaire or inactivated virus and studied for
apoptosis of CD3+8+ T cells. We first studied CD8 levels on T
cells. We found a 40% decline in CD8 levels in infected
cultures on day 4 and a 60% decline on day 8 post-infection
compared to uninfected control and inactivated virus-treated
cells (Table 1). Similar reduction was found in CD3 levels on
CD8 T cells as seen on CD3+4+ T cells. We also found an
increase in the number of FSClow cells in virus-infected
cultures as compared to controls (mean channel value <200;
20–22% in controls versus 31% infected cells on day 4 and
20% in controls versus 42% in infected cultures on day 8 post-
infection). We tried next to determine whether the FSClow
population was undergoing apoptosis by staining for Bcl2,
active caspase 3 and annexin-V markers. Fig. 2 shows that
40% of the CD3+8+ T cells were FSClow and Bcl2low (top left
panel) as compared to 20–21% Bcl2low in control and
inactivated virus-treated cells on day 4 PI. The percentage of
Bcl2low cells increased to 50% following Ebola infection as
compared to 16–21% Bcl2lowFSClow cells in controls on day 8
PI. Similar to the Bcl2 results, 37% of the cells were FSClow
cells and active caspase 3high versus 21–23% in controls and
inactivated virus-treated cells on day 4 PI. The percentage of
FSClow active caspase 3high cells in virus-infected cultures
increased to 55% as compared to 15–21% in controls on day 8
Fig. 1. CD4 T cells undergo massive cell death following viral infection. PBMCs from infected, uninfected control and inactivated virus-treated cultures were stained
for Bcl2, active caspase 3 and annexin-Vmarkers at day 4 and day 8 PI. The percentages of cells are indicated in each quadrant. x axis shows Bcl2, active caspase 3 and
annexin-V staining and y axis shows FSC population on days 4 and 8 post-infection. Mean fluorescent intensity for isotype control for Bcl2 was 20±4 (mean±SD), for
active caspase 3 was 40±10 and for annexin-V was 30±10 in five different experiments. Percentage of annexin-V+ cells on FSClow population matches with
Bcl2lowFSClow and FSClow active caspase 3high numbers on day 4 and day 8 PI. These data together suggest that 30–40% CD4 T cells are undergoing apoptosis
following virus infection by day 8 PI. This figure is a representative of five independent experiments.
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Fig. 2. Ebola virus causes CD8 T cell death. PBMCs were harvested on days 4 and 8 PI and stained for CD8, Bcl2 and active caspase 3 and annexin-V markers. The
percentages of cells are indicated in each quadrant. Isotype control values were the same as shown in Fig. 1. x axis shows Bcl2, active caspase 3 and annexin-V levels
and y axis represents FSC levels in controls, inactivated virus-treated and live virus-infected CD3+8+ cells on days 4 and 8 PI. These data together indicate that there is
a two to three-fold increase in Bcl2low, active caspase 3high and annexin-V+ cells following viral infection as compared to two other populations. This figure is a
representative of five independent experiments.
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infected with Ebola virus were FSClow (right panel; Fig. 2) as
compared to 1–3% cells in controls on day 4 PI. Numbers of
annexin-V+ cells were increased to 42% on day 8 following
virus infections whereas remained unchanged (1%) in controls
in the FSClow population. It is important to note that nearly all
annexin-V+ cells in controls and inactivated virus-treated
populations are blasts (FSChigh cells) and not the apoptotic
cells (FSClow) unlike in the virus-infected group. Together, these
results suggest that 30–40% of CD8 Tcells were undergoing cell
death by day 8 PI after viral infection.
Ebola virus kills the majority of macrophages
PBMCs infected with live virus or treated with inactivated
virus or left in media alone were stained for CD14. PBMCs were
analyzed for forward scatter on CD14+ cells and CD14 levels in
all three cultures. Table 1 shows that there is a 85% reduction in
CD14 levels in virus-infected cultures on day 4 and a 94%
reduction on day 8 post-infection as compared to uninfected
controls and inactivated virus-treated cells. Panel A in Fig. 3
shows forward scatter of CD14+ cells on days 4 and 8 PI. On day
4 PI, the numbers of FSClow cells were lower in controls and
inactivated virus-treated populations (27–33%) and increased
2.5 times after virus infection (77%). The percentage of FSClow
cells remained the same at day 8 PI (30–35%) in controls and
inactivated virus-treated populations whereas it increased to
86% in the virus-infected population. To further confirm that
FSClow cells were apoptotic, we stained them for Bcl2, active
caspase 3 and annexin-V markers. We found that 18–25% of the
cells were FSClow Bcl2low in controls and inactivated virus-
treated populations on day 4 PI (Fig. 3B) whereas 70% of the
virus-infected population was Bcl2lowFSClow. The percentage of
Bcl2low cells was increased to 82% in virus-infected populations
by day 8 PI whereas it remained unchanged in controls and
inactivated virus-treated groups (Fig. 3B). We next studied the
frequency of active caspase 3high cells in FSChigh and FSClow
populations. We found that both FSChigh and FSClow
populations of CD14+ cells had high levels of active caspase
3 (Fig. 3C). In controls and inactivated virus-treated groups,
65–71% of the cells were FSChigh and active caspase 3high
whereas 71% of virus-infected cell population were caspase
3high and FSClow. A similar pattern was found on day 8 PI, 62–
68% of the cells were FSChigh active caspase 3high in controls
and inactivated virus-treated populations and 76% of the cells
were FSClow active caspase 3high in the Ebola virus-infected
population (Fig. 3C). Fig. 3D shows that 63–72% annexin-V+
cells were FSChigh in controls and inactivated virus-treated
group whereas 73% annexin-V+ cells were FSClow in the
virus-infected group on day 4 PI. This percentage of annexin-
V+FSClow cells was increased to 90% at day 8 PI in virus-
infected population while it remained unchanged in the con-
trols. In addition, using Ebola-GFP virus, we further confirmed
that 95–98% of CD14+ cells were infected on day 4 PI as
shown previously (Towner et al., 2005) suggesting that most
of the macrophages that were undergoing apoptosis were also
infected with Ebola virus.Virus induces apoptosis in Fas and FasL positive T cells and
macrophages
We next determined which population within the CD4, CD8
or CD14 cells was undergoing apoptosis by day 4 PI. To study
this, CD4, CD8 or CD14 cells were stained for Fas or FasL and
gated on FSChigh and FSClow populations. Fig. 4A shows that
13% of the CD3+4+ cells were Fas+ and large (FSChigh) and
4% Fas+ cells were small (FSClow) in controls and inactivated
virus-treated populations. This percentage was reversed in the
virus-infected group, i.e. 14% cells were Fas+FSClow and 4%
were Fas+FSChigh. A similar pattern was found in CD3+8+ cells:
8–13% of the cells were FSChigh Fas+ in control and inactivated
virus-treated populations as compared to 5% following virus
infection; 11% of the CD3+8+ cells were FSClowFas+ as
compared to 1 to 2% in controls. Similarly in macrophages,
53–54% cells were Fas+FSChigh in controls as compared to
11% in the virus inoculated cell populations. The percentage of
Fas+FSClow cells was 43% in virus-infected populations as
compared to 2% in the controls.
Fig. 4B shows the frequency of FasL+ cells in FSChigh and
FSClow populations in different cell types. The percentage of
FasL+FSClow cells was 17% in CD4 T cells after viral infection
as compared to 7% in the controls (Fig. 4B). At the same time
the frequency of FasL+FSChigh cells was 3% following virus
infection as compared to 17% in the controls. Similarly in CD8
T cells, there were a two-fold higher numbers of FasL+FSClow
cells and a two to three-folds lower numbers of FasL+FSChigh
cells were found in virus-infected population as compared to the
controls and inactivated virus-treated populations (Fig. 4B). In
the macrophage population, the percentage of FasL+FSClow
was four times higher in the viral infection group (69%) as
compared to the controls (14–19%). At the same time the
percentage of FSChigh cells was 21% after virus exposure as
compared to 63–65% in the controls. Furthermore we found
that Fas+FSClow/FasL+FSClow cells were also Bcl2low (data not
shown) in CD4, CD8 and CD14 cells, confirming that these
cells are undergoing cell death. These data together suggest that
Ebola virus induces apoptosis in already activated cells and in
particular targets Fas/FasL positive cells.
Virus induces TRAIL mRNA in CD4 and CD8 T cells but not in
macrophages
We isolated CD4, CD8 and macrophages using magnetic
bead columns on day 7 PI. Cells were checked for purity by
staining and cell numbers were normalized before lysis. RNAse
protection assay (RPA) was performed. From the multiple
proapoptotic genes included in the multi-probe hApo-3d used,
only TRAIL mRNA showed a significant induction. Fig. 5
shows the levels of TRAIL mRNA for purified CD4 and CD8 T
cells in uninfected controls, inactivated virus-treated cells and
Ebola virus-infected cells. The mRNA levels of housekeeping
gene L32 from the same RPA experiment are shown in the
bottom panel. It was apparent that in CD4 and CD8 T cells L32
mRNA in virus-infected cells was much less than in control and
inactivated virus-treated cells. In spite of that, TRAIL mRNA in
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in the two experimental controls. Quantitative densitometric
measurements indicated that in virus-infected CD4 T cells there
was approximately a two-fold increase in TRAIL mRNA levels
compared to the two control populations (Fig. 5B). In CD8 T
cells, TRAIL mRNA levels were approximately 3 times higher
than in uninfected control and inactivated virus-treated cells
(Fig. 5B). Surprisingly, we did not find any difference in TRAIL
mRNA levels in virus-infected macrophages on day 2 and day 7
PI (data not shown) despite previous report on human
monocytes using Ebola Zaire 95' subtype by Hensley et al.
(Hensley et al., 2002). These data together suggest that T cells
probably used the TRAIL pathway for the induction of apoptosis
whereas macrophages might be using a pathway other than
TRAIL to undergo apoptosis.
Discussion
In this study, we have provided direct evidence of apoptosis
in lymphocytes caused by Ebola virus infection. Our findings
suggest that Ebola virus induces apoptosis in CD4 and CD8 T
cells. Previous reports have suggested a decrease in CD4 and
CD8 T cell numbers in patients with a fatal outcome around
day 6 or 8 post-exposure (Baize et al., 1999; Sanchez et al.,
2004). Our data clearly indicate that, on day 8 following
infection, 30–40% of the CD4 and CD8 T cells are dead. This
observation may help to explain why fatal cases do not have
anti-Ebola antibodies at death and survivors have a delay in the
production of anti-Ebola IgG. Our findings show that Ebola
virus causes massive death of CD4 T cells which are required
for IgM to IgG switching. Other immune cells like CD8 T cells
involved in the control of Ebola infection are also undergoing
cell death and cannot control virus levels in the host. A number
of other factors like IFN-α could play an important role in
controlling infection. We and others have found a decrease in
IFN-α levels during infection ((Baize et al., 1999; Gupta et al.,
2001). High levels of TNF-α, MCP-1, MIP1-α and other
cytokines/chemokines were present between day 1 and 7 post-
infection (Bray and Mahanty, 2003). These cytokines may play
an important role in recruiting macrophages and T cells at the
site of infection and may cause cell death. We have also
studied but not reported in this study apoptosis in NK cells and
B cells. We did not find any significant difference in Bcl2 and
active caspase 3 levels in these populations compared to
controls until day 8 PI (data not shown); suggesting that B
cells themselves are not affected and may not be responsible
for the delay in appearance or low levels of anti-Ebola
antibodies. A previous report in macaques has shown similar
results on B cell following infection over a period of time
(Reed et al., 2004).Fig. 3. Ebola virus kills the majority of macrophages by day 8 PI. PBMCs, either infe
cells, were stained for CD14, Bcl2, active caspase 3 and annexin-V markers at day 4
shows forward scatter for CD14+ cells. Panel B shows Bcl2 levels in FSClow and FS
populations. Panel D shows annexin-V staining in different FSC populations. Isotype
70% of macrophages are Bcl2low, active caspase 3high and annexin-V+ by day 4 PI aft
are shrinking after virus exposure. This experiment is repeated five times.FSChigh T cells have activated phenotype and are dividing,
which have been shown previously (Bonnevier and Mueller,
2002; Schmidt and Mescher, 1999). Data in Figs. 1 and 2 were
divided in FSChigh and FSClow populations. To confirm that
FSChigh cells are activated, wemarked FSChigh CD3+4+/FSChigh
CD3+8+ cells for CD25. We found that only FSChigh cells have
higher levels on CD25 as compared to FSClow cells (data not
shown). Our data indicate that there are two to three-fold higher
numbers of Bcl2low, active caspase 3high and annexin-V+ CD4
and CD8 T cells present following virus exposure compared to
controls. Of note, active caspase 3 and annexin-V are present in
both blasts (FSChigh) and in apoptotic cells (FSClow) however
there is a significantly higher numbers of apoptotic cells
showing active caspase 3 and annexin-V in virus-infected
populations than the controls. The numbers of blast cells
showing higher levels of active caspase 3 and annexin-V after
virus infection do not significantly increase, in fact the staining
for these markers is reduced on FSChigh cells as compared to the
controls, suggesting that more death than activation is going on
in virus-infected cultures. Our data show that 60–70% of the
infected macrophages had lower levels of Bcl2 and were
positive for annexin-V. We also found that most of the Ebola-
infected macrophage population lost adherence by day 4 PI and
99% of the cells were infected with Ebola virus {determined by
Ebola-GFP} suggesting that the virus may directly induce death
in macrophages. There are no previous reports of Ebola virus
infecting T cells. Recently published study has shown that
immunosuppressive glycopeptide in Ebola virus can cause cell
death without infection (Yaddanapudi et al., 2006). The
mechanisms of apoptosis in macrophages and T cells are still
unknown.
Our findings show that Ebola virus induces apoptosis in Fas+
and FasL+ T cells and macrophages. In all the cell types studied,
we saw a significant reduction in the numbers of blast cells
positive for Fas/FasL. All blast cells which were positive for
Fas/FasL in the infected cultures on the top right panel in Figs.
4A and B moved down in the quadrant (Figs. 4A and B, top
right panel to bottom right panel) in virus challenged group and
were much smaller in size. These small cells (FSClowFas+) also
have low levels of Bcl2 (data not shown) suggesting that they
were undergoing cell death following virus challenge. Of note
the total numbers of Fas+/FasL+ cells did not change i.e. the
number of Fas+FSClow plus Fas+FSChigh cells in virus-infected
cultures was not very different from total Fas+ cells in the
controls. This indicates that there is no induction of Fas/FasL on
T cells and macrophages. Previous reports have shown
upregulation of Fas mRNA levels in infected patients (Baize
et al., 1999) and macaques (Reed et al., 2004). Another report
mentions no difference in Fas levels in infected patients as
compared to controls (Sanchez et al., 2004). By using the flowcted with Ebola virus or treated with gamma-irradiated killed virus or uninfected
and day 8 PI. The percentages of cells are indicated in each quadrant. Panel A
Chigh cells on CD14+ cells. Panel C shows staining for active caspase 3 in FSC
control values were the same as mentioned in Fig. 1. Data together indicate that
er virus challenge and are FSClow. It also indicates that most of the macrophages
Fig. 4. Ebola virus induces apoptosis in Fas+/FasL+ cells. Panel A shows Fas expression in CD4, CD8 T cells and in macrophages. Respective cell populations were
screened for Fas levels in FSClow and FSChigh cells. The percentages of positive cells are indicated in each quadrant. Mean fluorescent intensity of isotype control for
Fas was 50±10 (mean±SD) and for FasL was 30±10 from three different experiments. Panel B indicates FasL levels in CD4, CD8 T cells and macrophages. FasL
levels plotted against forward scatter. This figure is a representative of three independent experiments. Data suggest that Ebola virus might target Fas+/FasL+ Tcells and
macrophages and may induce death signal in these populations.
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Fig. 5. Induction of TRAIL mRNA in Ebola virus-infected CD4 and CD8 T
cells. RNAse protection assay was performed in total RNA isolated from
CD3+4+ and CD3+8+ cells treated with media, gamma-irradiated inactivated
Ebola virus or infected with Ebola virus at day 7 PI using hApo-3d multi-probe
(A). Quantitative densitometric measurements of TRAIL gene expression
shown in panel B presented as a percentage of housekeeping L32 gene
expression. The levels of TRAIL mRNA among samples were determined by
using the phosphoImager system. The data are representative of two
independent experiments.
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protein levels of Fas and FasL on various cell types.
TRAIL has been shown to play an important role in
apoptosis in HIV-infected CD4 T cells (Miura and Koyanagi,
2005) and in primary small airway and tracheal–bronchial cells
by respiratory syncytial virus (Kotelkin et al., 2003). Our study
clearly shows a significant increase in TRAIL mRNA levels in
CD4 and CD8 T cells on day 7 PI. A significant number of cells
were dying after virus exposure suggesting that TRAIL might
be responsible for apoptosis in these cells. Surprisingly, we did
not find any difference in TRAIL levels in infected macro-
phages from that of controls suggesting that TRAIL is not
responsible for apoptosis in these cells. We know that virus
infection in macrophages upregulates TNF-α and many other
cytokines (Gupta et al., 2001). The possible role of TNF-α, Fas,
FasL or TRAIL in the induction of apoptosis in PBMCs infected
with Ebola virus needs further study.
Our data clearly indicate that Ebola virus causes massive
death of human CD4 and CD8 T cells and clarifies why there is
a delay in the production of anti-Ebola IgG in infected patients.
In addition these data show that macrophages which are the
reservoir for the virus are also dying early in infection. Further
studies are needed to elucidate the details of the mechanisms of
virus-mediated apoptosis in T cells and macrophages.Materials and methods
Isolation of PBMCs and infection
A blood sample from healthy individuals was collected and
layered on ficoll gradient medium (ICN Biomedicals, Aurora,
OH). Purified PBMCs were counted and cultured on 6-well
plates at 12×106 cells/well in RPMI medium with 10% FCS
supplemented with antibiotics and L-glutamine. Cells were in-
cubated for 1 h to allow macrophage adherence. After removing
the non-adherent cells, adherent cells were either infected with
the Mayinga strain of Zaire Ebola virus (passaged twice in Vero
E6 cells) at a multiplicity of infection (MOI) of 0.5 or treated
with same amount of inactivated virus (gamma irradiation:
5×106 rads) for 1 h, along with uninfected controls as
previously described (Gupta et al., 2001). After incubation,
non-adherent cells were added back to the inoculated cells;
activation and apoptosis marker staining was done on specific
days PI. Using the same MOI of an Ebola-GFP virus we found,
in a separate experiment, that 90% of the macrophages were
infected by day 4 PI as shown previously (Towner et al., 2005).
All the virus manipulations were done in a biosafety level
(BSL)-4 laboratory at the Centers for Disease Control and Pre-
vention in Atlanta.
Surface and intracellular staining
On days 4 and 8 PI, adherent and non-adherent cells were
resuspended and distributed in 96 well plates at 1×106 cells/
well. Cells were labeled as previously described (Gupta et al.,
2005). For surface markers, cells were incubated with 50 μl of
anti-CD3-PerCP, CD4-APC, CD8-APC, CD19-APC, CD14-
APC, CD56-APC, Fas-FITC, FasL-PE and isotype controls for
30 min on ice. All antibodies were purchased from BD
Pharmingen (San Diego, CA). After surface staining, cells were
washed and permeabilized using a cytofix kit (BD Pharmingen,
CA) according to the manufacturer's instructions. After per-
meabilization, cells were incubated with active caspase-3-PE,
Bcl2-PE and isotype controls for 30 min on ice. Un-adsorbed
antibodies were washed away by centrifugation and cells were
fixed with 0.2% paraformaldehyde and stored at 4 °C until
processing. Approximately 50,000 cells were counted in each
sample. Cells were gated on CD3, CD4, CD8 and CD14
markers above MFI values of their isotype controls (MFI of 20,
30, 30 and 40 respectively).
To further study apoptosis, cells were also stained for
annexin-V in conjunction with CD3-PE, CD4-APC, CD8-APC,
CD19-APC, CD14-APC and CD56-APC markers. All cell
staining was performed in the BSL-4 laboratory. Cell signals
were acquired on FACScalibur inside the BSL-4 laboratory and
analyzed on FACS FlowJo (BD Biosciences) software.
Isolation of CD4, CD8 and macrophages using magnetic beads
100–120×106 PBMCs from infected, uninfected and killed
virus-treated cultures were incubated with CD14-magnetic
beads (Milteneyi Biotech, Auburn, CA) for 15 min on ice.
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lumn according to the manufacturer's instructions. The unbound
fraction was collected in separate tubes. The column was
removed from the magnet and the retained fraction was washed
out. Bound and unbound fractions were pelleted and then
counted. CD14 negative cells were then incubated with CD4
beads following the same procedure. The CD14/CD4 negative
cells were incubated with CD8 beads and the same procedure
was repeated. An aliquot of each fraction was tested for purity by
staining with their respective marker antibodies. Cell signals
were acquired on the flow cytometer (FACScalibur) and ana-
lyzed on FlowJo software. Each fraction was 90–95% pure
using a flow cytometry analysis. Cells were normalized and
lysed using Tri-pure reagent (Boehringer Mannheim Biochem-
icals, Indianapolis, IN) for further study of apoptotic signals.
RNAse protection assay
Total RNA from each experimental group was extracted
using Tri-Pure reagent (1 ml per 5×106 cells) followed by
chloroform extraction and matrix purification (Rnaid kit Bio-
101, La Jolla, CA). The levels of proapoptotic gene
transcripts were then determined using RiboQuant RPA kit
and probe hApo-3d (PharMingen, San Diego, CA) following
instructions provided by the manufacturer. Quantitative
measurements of the levels of mRNA were made using the
phosphoImager system. The values obtained were normalized
against the mRNA of the housekeeping gene L32 loaded in
the same lane.
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